The UCR accepts referrals from GPs, Hampshire hospitals, ambulance services, families, and patients themselves. It helps ...

GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines ...

Clin Asst Prof Sewa Duu Wen, Head and Senior Consultant of Respiratory and Critical Care Medicine at Singapore General ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...

An expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed seven new medicines for approval this ...

At a national conference in Patna, specialists highlighted a troubling trend: women are increasingly suffering from COPD. The ...

NIHR Newcastle CRDC recruits the first patient in the world to a clinical study into a common lung condition: United Kingdom Friday, December 12, 2025, 17:00 Hrs [IST] A team at t ...

Arexvy is GSK’s adjuvanted recombinant vaccine designed to prevent lower respiratory tract disease (LRTD) caused by RSV. Initially approved for adults aged 60 and older, as well as those aged 50-59 ...

A visionary, David Keith Lynch died at age 78 on January 15, 2025, in Los Angeles from complications of emphysema and chronic ...

The recommendation by the CHMP should now result in approval of Arexvy in the broader age range in February next year, and ...

GSK secures FDA approval for its oral gonorrhoea drug as EMA backs expanded RSV vaccine and additional respiratory treatments ...

GSK expects the European Commission to decide on approvals for both depemokimab and Nucala in the first quarter of 2026. GSK shares were 0.1% higher at 1,822.50 pence each on Friday afternoon in ...